Dipartimento Cardiovascolare, Policlinico S. Orsola, Bologna, Italy.
Am J Cardiol. 2013 Dec 15;112(12):1860-6. doi: 10.1016/j.amjcard.2013.08.010. Epub 2013 Sep 21.
Although it has been shown that elevated white blood cell count (WBCc) on presentation is associated with an increased risk of cardiac mortality in patients with ST-segment elevation myocardial infarction (STEMI), the responsible mechanisms are unknown. We therefore sought to investigate whether elevated WBCc is associated with increased infarct size measured with cardiac magnetic resonance imaging 30 days after primary percutaneous coronary intervention in the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction trial. INFUSE AMI randomized patients with STEMI and proximal or mid-left anterior descending coronary artery occlusion to bolus intracoronary abciximab versus no abciximab and to manual aspiration versus no aspiration. WBCc at hospital admission was available in 407 of 452 randomized patients. Patients were stratified according to tertiles of WBCc. At 30 days, a significant stepwise increase in infarct size (percentage of total left ventricular mass) was apparent across tertiles of increasing WBCc (median [interquartile range] for tertiles I vs II vs III = 11.2% [3.8% to 19.6%] vs 17.5% [0.5% to 22.9%] vs 19.1% [13.7 to 26.0], respectively, p <0.0001). Absolute infarct mass in grams and abnormal wall motion score were also significantly increased across tertiles of WBC. By multivariate linear regression analysis, WBCc was an independent predictor of infarct size along with intracoronary abciximab randomization, age, time from symptom onset to first device, proximal left anterior descending location, and baseline TIMI flow of 0/1. In conclusion, in patients with anterior wall STEMI, an elevated admission WBCc is a powerful independent predictor of infarct size measured with cardiac magnetic resonance imaging 30 days after primary percutaneous coronary intervention.
虽然已经表明,在 ST 段抬高型心肌梗死(STEMI)患者就诊时白细胞计数(WBCc)升高与心脏死亡率增加相关,但负责的机制尚不清楚。因此,我们试图研究白细胞计数升高是否与 30 天后接受直接经皮冠状动脉介入治疗的患者的心脏磁共振成像测量的梗死面积增加有关。INTENSE AMI 试验将 STEMI 患者和近端或中段前降支闭塞患者随机分为冠状动脉内给予阿昔单抗推注与不给阿昔单抗以及手动抽吸与不给抽吸。452 名随机患者中有 407 名患者的入院时 WBCc 数据可用。根据 WBCc 的三分位数对患者进行分层。30 天时,随着 WBCc 三分位数的增加,梗死面积(左心室总质量的百分比)明显呈递增趋势(三分位数 I、II 和 III 的中位数[四分位数间距]分别为 11.2%[3.8%19.6%]、17.5%[0.5%22.9%]和 19.1%[13.7%~26.0%],p<0.0001)。克级的绝对梗死质量和异常壁运动评分也随着 WBC 的三分位数显著增加。通过多元线性回归分析,WBCc 是梗死面积的独立预测因子,与冠状动脉内给予阿昔单抗、年龄、症状发作至首次器械时间、前降支近端部位和基线 TIMI 血流 0/1 有关。总之,在前壁 STEMI 患者中,入院时升高的 WBCc 是直接经皮冠状动脉介入治疗 30 天后心脏磁共振成像测量的梗死面积的有力独立预测因子。